AIM ImmunoTech: ‘Activist Group slate is wrong vhoice’ for shareholders

AIM ImmunoTech (AIM) issued a presentation highlighting why shareholders should NOT elect the four director candidates nominated by a group of activist investors as part of their multi-year attempt to take over AIM’s Board of Directors at the upcoming 2024 Annual Meeting of Stockholders , presently scheduled for December 17. “The Activist Group nominees have not proposed a compelling plan for AIM and appear to be focused on seeking reimbursement for their past expenses. To settle, the Activist Group is demanding upwards of $8 M in litigation expenses from AIM for money its members spent on failed lawsuits against the Company. If the Activist Group’s nominees are elected to the Board, they have blatantly stated in their definitive proxy statement: “In addition to the foregoing amount, each of Mr. Kellner, Mr. Deutsch and Mr. Chioini intend to seek reimbursement from the Company of all expenses they incurred in connection with their solicitation for the 2023 Annual Meeting including related litigation expenses , which amounts to approximately $5.3 M… and they do not intend to submit the question of such reimbursement to a vote of security holders of the Company.” The Activist Group Slate is the WRONG Choice for AIM Shareholders,” the company said.